A proven safe and well-tolerated non-drug treatment

For migraine headache1

In PRESTO, the most common device-related adverse events ≥2% were application-site discomfort (2.5% vs 0.8%),  application-site erythema (0% vs 2.4%), application-site pain (0% vs 2.4%), and dizziness (0% vs 1.6%) in the gammaCore (nVNS) and sham arm, respectively. Most adverse events were mild and transient and occurred primarily during administration.

PRESTO Adverse Device-Related Events (Safety Population)1

For episodic cluster headache2,3

In ACT1, the most common adverse device-related events were mild and transient, and occurred primarily during administration2,3

 In ACT2, no adverse device-related events were observed in ≥5% of patients in any treatment group2,4

References: 1. Tassorelli C, et al. Presented at: 11th European Headache Federation (EHF) Congress; December 1-3, 2017; Rome, Italy. O9. 2. gammaCore Instructions for Use. Basking Ridge, NJ: electroCore, Inc.; 2018. 3. Silberstein SD, Mechtler LL, Kudrow DB, et al; ACT1 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56(8):1317-1332.4. Goadsby PJ, de Coo IF, Silver N, et al; ACT2 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959-969.